FDA commissioner’s drug review plan sparks alarm
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored…
Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide.…
How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…
Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk
Lawsuit alleges anti-competitive conduct designed to suppress lawful compounding pharmaceuticals and limit patient choice GILBERT, Ariz., Jan. 14,…
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
jetcityimage / iStock Editorial via Getty Images Lilly posted 53.9% revenue growth and 480% net income growth driven…
Lilly in talks to buy Ventyx Biosciences for more than $1 billion, WSJ reports
Jan 6 (Reuters) – Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1…
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy
This article first appeared on GuruFocus. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped roughly 21% in premarket trading after the U.S.…
Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access
This article first appeared on GuruFocus. Weight-loss drugs known as GLP-1s are increasingly reshaping healthcare and the pharmaceutical…
9 big pharmaceutical companies agree to lower drug prices for Medicaid
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription…
Eli Lilly’s pill solves the biggest problem with weight loss
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly…